Natco Pharma buzzes on launch of Tamiflu tablets
DSIJ Intelligence / 12 Dec 2016
Natco Pharma has launched the first generic equivalent of Tamiflu oral capsules (Roche’s trade name for Oseltamivir phosphate capsules), 30 mg, 45 mg and 75 mg through its marketing partner Alvogen in the USA market.
Natco Pharma has launched the first generic equivalent of Tamiflu oral capsules (Roche’s trade name for Oseltamivir phosphate capsules), 30 mg, 45 mg and 75 mg through its marketing partner Alvogen in the USA market. Tamiflu oral capsules had US sales of approximately USD 403 mn (Rs 2,723 crore) for 12-month ending December 2015, according to IMS Health.
Tamiflu is a US registered trademark of Hoffman La-Roche Inc. Corporation. Natco and Alvogen are not affiliated with Hoffman La-Roche Inc.
On the financial front, Natco Pharma’s revenue increased 75.56 per cent to Rs 415 crore in Q2FY17 as compared to the same period in the previous financial year. The company’s EBITDA too rose 80.05 per cent to Rs 105 crore in Q2FY17 on a yearly basis. Its net profit also soared by more than two times to Rs 66 crore in Q2FY17 on a yearly basis.
The share price of Natco Pharma increased 2.53 per cent on the bourses in early trades and is trading at Rs 599.5 on intra-day basis.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.